New Delhi: Hours after the UK gave the clearance to the Oxford University-AstraZenecas Covid-19 vaccine for use after authorisation by the country’s medicines regulator, all eyes are now on India.
The Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC) is all set to hold a meeting on December 30 to take a call on Covishield vaccine against Covid-19 developed by the Serum Institute of India (SII) and AstraZeneca-Oxford University.
If sources are to be believed, then the Covishield vaccine is likely to get approval for emergency use in India.
Serum Institute’s chief Adar Poonawalla expressed happiness over the decision. “This is a great and encouraging news. We will wait for the final approval from Indian regulators,” he told NDTV.
The Serum Institute of India had last week submitted some additional data required by the Drug Controller General of India (DCGI), reported India Today.
Bharat Biotech, Serum Institute of India and Pfizer had applied to the DCGI seeking emergency use authorisation for their Covid-19 vaccines early this month.
